周三,Stifel分析师维持对Denali Therapeutics Inc.(NASDAQ:DNLI)股票的买入评级,目标价为37.00美元。根据 InvestingPro 数据,分析师对该股票保持高度看好,共识评级为"强烈买入",目标价范围在24美元至87美元之间。
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
The CDC recommends a single dose of any FDA-approved RSV vaccine for all adults ages 75 years and older, as well as for 60- ...
The FDA has set maximum levels for lead in baby food. A new California law requires baby food makers selling products in the ...
Years of research have showed that pulse oximeters yield less accurate readings for people with darker skin tones, and now ...
By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...
The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...
Cantex Pharmaceuticals, Inc.是一家临床阶段制药公司,专注于开发癌症和其他危及生命的疾病的变革性疗法。该公司宣布,美国食品药品监督管理局 (FDA) 授予 Cantex 的 azeliragon ...
TUESDAY, Jan. 7, 2025 (HealthDay News) -- The U.S. Food and Drug Association (FDA) released the first-ever guidelines for ...
But consumer advocates say the Food and Drug Administration's new guidance on lead limit in baby food doesn't go far enough.
要知道 在目前市场中面临着对GLP-1药物的高需求背景之下,得供应量者则可得天下。 而为解决供应短缺的问题,礼来与诺和诺德也使出了浑身解数来应对。其中礼来曾以53亿美元的额外投资,用于生产Mounjaro和Zepbound的活性成分;诺和诺德也在今年 ...